Showing results (41-50 of 253) with videos related to
Sort By:
Pageof 26
Diabetes Care|December 29, 2007
Plasma concentration of asymmetric dimethylarginine (ADMA) predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathyMaria Lajer, Lise Tarnow, Anders Jorsal, et al.European Journal of Endocrinology|December 31, 2005
Plasma osteoprotegerin levels are associated with glycaemic status, systolic blood pressure, kidney function and cardiovascular morbidity in type 1 diabetic patientsLars Melholt Rasmussen, Lise Tarnow, Troels Krarup Hansen, et al.Diabetes Care|August 27, 2005
Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over studyKasper Rossing, Katrine J Schjoedt, Ulla M Smidt, et al.Journal of the American Society of Nephrology : JASN|October 22, 2003
Genetic variation in the Renin-Angiotensin system and progression of diabetic nephropathyPeter Jacobsen, Lise Tarnow, Bendix Carstensen, et al.Kidney International|February 12, 2017
Intensified multifactorial intervention in type 2 diabetics with microalbuminuria leads to long-term renal benefitsJens Oellgaard, Peter Gæde, Peter Rossing, et al.Diabetes Care|December 28, 2002
Optimal dose of candesartan for renoprotection in type 2 diabetic patients with nephropathy: a double-blind randomized cross-over studyKasper Rossing, Per K Christensen, Birgitte V Hansen, et al.Diabetes Care|February 28, 2004
Elevated plasma asymmetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephropathy in type 1 diabetesLise Tarnow, Peter Hovind, Tom Teerlink, et al.Kidney International|August 18, 2005
Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuriaKasper Rossing, Katrine J Schjoedt, Berit R Jensen, et al.Journal of Diabetes and Its Complications|October 5, 2018
Application of urinary proteomics as possible risk predictor of renal and cardiovascular complications in patients with type 2-diabetes and microalbuminuriaJens Oellgaard, Peter Gæde, Frederik Persson, et al.Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|January 25, 2003
Time course of the antiproteinuric and antihypertensive effect of losartan in diabetic nephropathySteen Andersen, Peter Jacobsen, Lise Tarnow, et al.Pageof 26